April 2014
CRT exclusive agreement: Vertebrate Antibodies Ltd reached an agreement with Cancer Research Technology (CRT) to exclusively license a number of their monoclonal antibodies for Research Only. The antibodies are specific towards the following human targets; BCLAF1, CCT2, CYP1A2, CYP1A, CYP2A6, CYP2E1, CYP2R1, CYP4F11, CYP4A11, CYP4V2, CYP4Z1, CYP3A4, CYP3A5, [...]